Primary sclerosing cholangitis: A review and update on therapeutic developments

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 2, 2013, Pages 103-114

  Tabibian, James H ^a   Lindor, Keith D ^b  

^a MAYO CLINIC   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

antibacterial agents; bile duct diseases; cholangiography; cholangiopancreatography; endoscopic retrograde; enterohepatic circulation; fibrosis; genes; magnetic resonance imaging; ras; TOR serine threonine kinases

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DOCOSAHEXAENOIC ACID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINE; PENICILLAMINE; PENTOXIFYLLINE; PIRFENIDONE; PLACEBO; RAPAMYCIN; SILYMARIN; TACROLIMUS; URSODEOXYCHOLIC ACID; VANCOMYCIN;

DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOCYTE; MONOTHERAPY; MORTALITY; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-BACTERIAL AGENTS; CHOLANGITIS, SCLEROSING; DISEASE MODELS, ANIMAL; ENDOSCOPY, DIGESTIVE SYSTEM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; RECEPTORS, LYMPHOCYTE HOMING; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84873120585     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.80     Document Type: Review

References (119)

1. Aron JH, Bowlus CL. The immunobiology of primary sclerosing cholangitis. Semin. Immunopathol. 31(3), 383-397 (2009).
2. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am. J. Gastroenterol. 102(5), 1042-1049 (2007). (Pubitemid 46705300)
3. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract. Res. Clin. Gastroenterol. 25(6), 727-739 (2011).
4. Tabibian JH, O'Hara SP, Larusso NF. Primary sclerosing cholangitis: the gut- liver axis. Clin. Gastroenterol. Hepatol. 10(7), 819; author reply 819-820 (2012).
5. Tabibian JH, Lindor KD. Challenges of cholangiocarcinoma detection in patients with primary sclerosing cholangitis. J. Anal. Oncol. 1(1), 5 (2012).
6. Bambha K, Kim WR, Talwalkar J et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125(5), 1364-1369 (2003). (Pubitemid 37409756)
7. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 54(5), 1842-1852 (2011).
8. Wiesner RH, Grambsch PM, Dickson ER et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 10(4), 430-436 (1989). (Pubitemid 19255462)
9. Alabraba E, Nightingale P, Gunson B et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 15(3), 330-340 (2009).
10. Graziadei IW. Live donor liver transplantation for primary sclerosing cholangitis: is disease recurrence increased? Curr. Opin. Gastroenterol. 27(3), 301-305 (2011).
11. Landaverde C, Ng V, Sato A, Tabibian J, Durazo F, Busuttil R. De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis. Ann. Hepatol. 8(4), 379-383 (2009).
12. Bansi DS, Fleming KA, Chapman RW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 38(3), 384-389 (1996). (Pubitemid 26074319)
13. Rankin JG, Boden RW, Goulston SJ, Morrow W. The liver in ulcerative colitis; treatment of pericholangitis with tetracycline. Lancet 2(7112), 1110-1112 (1959).
14. Delbet P. Rétrécissement du choledoque: cholecystoduodenostomie. Bulletins et Memoires de la Societe Mationale de Chirurgie 50, 3 (1924).
15. Mistilis SP, Skyring AP, Goulston SJ. Effect of long-term tetracycline therapy, steroid therapy and colectomy in pericholangitis associated with ulcerative colitis. Australas. Ann. Med. 14(4), 286-294 (1965).
16. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 95(4), 1036-1042 (1988).
17. Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 95(9), 2333-2337 (2000).
18. Allison MC, Burroughs AK, Noone P, Summerfield JA. Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study. J. Hepatol. 3(1), 118-122 (1986). (Pubitemid 16052763)
19. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 86(1), 57-61 (1991).
20. Schramm C, Schirmacher P, Helmreich- Becker I, Gerken G, zum Büschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann. Intern. Med. 131(12), 943-946 (1999). (Pubitemid 30005034)
21. Zhang L, Lewis JT, Abraham SC et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am. J. Surg. Pathol. 34(1), 88-94 (2010).
22. Lindor KD. New treatment strategies for primary sclerosing cholangitis. Dig. Dis. 29(1), 113-116 (2011).
23. Sah RP, Chari ST. Autoimmune pancreatitis: an update on classification, diagnosis, natural history and management. Curr. Gastroenterol. Rep. 14(2), 95-105 (2012).
24. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 106(2), 494-499 (1994). (Pubitemid 24041229)
25. Wiesner RH Steiner B, LaRusso NF, Lindor KD, Baldus WP. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis. Hepatology, 14, Abstract 63A (1991).
26. Van Thiel DH, Carroll P, Abu-Elmagd K et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am. J. Gastroenterol. 90(3), 455-459 (1995).
27. Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int. 27(4), 451-453 (2007). (Pubitemid 46534566)
28. Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 95(9), 2338-2342 (2000).
29. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci. 49(1), 1-4 (2004). (Pubitemid 38183736)
30. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 100(2), 308-312 (2005). (Pubitemid 40314514)
31. Hommes DW, Erkelens W, Ponsioen C et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J. Clin. Gastroenterol. 42(5), 522-526 (2008). (Pubitemid 351572276)
32. Angulo P, Bharucha AE, Jorgensen RA et al. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig. Dis. Sci. 44(3), 602-607 (1999). (Pubitemid 29137974)
33. Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur. J. Gastroenterol. Hepatol. 13(2), 171-175 (2001). (Pubitemid 32158211)
34. Angulo P, MacCarty RL, Sylvestre PB et al. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci. 47(1), 157-161 (2002). (Pubitemid 34075033)
35. Martin CR, Blanco PG, Keach JC et al. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment. Pharmacol. Ther. 35(2), 255-265 (2012).
36. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig. Dis. Sci. 53(6), 1716-1720 (2008). (Pubitemid 351624429)
37. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment. Pharmacol. Ther. 34(8), 901-910 (2011).
38. EASL. Clinical Practice Guidelines: management of cholestatic liver diseases. J. Hepatol. 51(2), 237-267 (2009).
39. Chapman R, Fevery J, Kalloo A et al.; American Association for the Study of Liver Diseases. Diagnosis and managementof primary sclerosing cholangitis. Hepatology 51(2), 660-678 (2010).
40. Kuiper EM, Hansen BE, de Vries RA et al.; Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 136(4), 1281-1287 (2009).
41. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N. Engl. J. Med. 336(10), 691-695 (1997).
42. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121(4), 900-907 (2001). (Pubitemid 32959399)
43. Olsson R, Boberg KM, de Muckadell OS et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129(5), 1464-1472 (2005). (Pubitemid 41597389)
44. Stanich PP, Björnsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig. Liver Dis. 43(4), 309-313 (2011).
45. Elfaki DA, Lindor KD. Antibiotics for the treatment of primary sclerosing cholangitis. Am. J. Ther. 18(3), 261-265 (2011).
46. Kozaiwa K, Tajiri H, Sawada A et al. Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine. J. Gastroenterol. Hepatol. 13(8), 825-829 (1998). (Pubitemid 28374900)
47. Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 27(5), 580-583 (1998). (Pubitemid 28492259)
48. Broccoletti T, Ciccimarra E, Spaziano M et al. Refractory primary sclerosing cholangitis becoming responsive after sulphasalazine treatment of an underlying silent colitis. Italian J. Pediatr. 28, 515-517 (2002). (Pubitemid 36383057)
49. Tada S, Ebinuma H, Saito H, Hibi T. Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis. J. Gastroenterol. 41(4), 388-389 (2006). (Pubitemid 43834384)
50. Boner AL, Peroni D, Bodini A, Delaini G, Piacentini G. Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int. J. Immunopathol. Pharmacol. 20(4), 847-849 (2007).
51. Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J. Pediatr. Gastroenterol. Nutr. 47(1), 61-67 (2008).
52. Färkkilä M, Karvonen AL, Nurmi H et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40(6), 1379-1386 (2004). (Pubitemid 39657012)
53. Silveira MG, Torok NJ, Gossard AA et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am. J. Gastroenterol. 104(1), 83-88 (2009).
54. Tabibian JH, Weeding E, Jorgensen RA et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment. Pharmacol.Ther. doi:10.1111/apt.12232 (2013) (In Press).
55. Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J. 18(7), 816-827 (2004).
56. O'Hara SP, Splinter PL, Trussoni CE, Gajdos GB, Lineswala PN, LaRusso NF. Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation. J. Biol. Chem. 286(35), 30352-30360 (2011).
57. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23(12), 2840-2855 (2005). (Pubitemid 46179475)
58. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med. 359(13), 1367-1380 (2008).
59. Fava G, Lorenzini I. Molecular pathogenesis of cholangiocarcinoma. Int. J. Hepatol. 2012, 630543 (2012).
60. Chen XM, O'Hara SP, Nelson JB et al. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-κB. J. Immunol. 175(11), 7447-7456 (2005). (Pubitemid 41713442)
61. O'Hara SP, Splinter PL, Gajdos GB et al. NFκB p50-CCAAT/enhancer- binding protein β (C/EBPβ)-mediated transcriptional repression of microRNA let-7i following microbial infection. J. Biol. Chem. 285(1), 216-225 (2010).
62. Fickert P, Fuchsbichler A, Wagner M et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (abcb4) knockout mice. Gastroenterology 127(1), 261-274 (2004). (Pubitemid 38962293)
63. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 66(21), 10517-10524 (2006). (Pubitemid 44799774)
64. Bataller R, Lemon SM. Fueling fibrosis in chronic hepatitis C. Proc. Natl Acad. Sci. USA 109(36), 14293-14294 (2012).
65. Seki E, De Minicis S, Osterreicher CH et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat. Med. 13(11), 1324-1332 (2007). (Pubitemid 350073596)
66. O'Hara SP, Tabibian JH, Splinter PL, Larusso NF. The dynamic biliary epithelia: molecules, pathways, and disease. J. Hepatol. doi:10.1016/j.jhep. 2012.10.011 (2012) (Epub ahead of print).
67. Harada K, Nakanuma Y. Cholangiopathy with respect to biliary innate immunity. Int. J. Hepatol. 2012, 793569 (2012).
68. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin. Liver Dis. 26(1), 3-21 (2006). (Pubitemid 43320723)
69. Björnsson E, Cederborg A, Akvist A, Simren M, Stotzer PO, Bjarnason I. Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand. J. Gastroenterol. 40(9), 1090-1094 (2005). (Pubitemid 41291359)
70. Eade MN, Brooke BN. Portal bacteraemia in cases of ulcerative colitis submitted to colectomy. Lancet 1(7603), 1008-1009 (1969).
71. Oriishi T, Sata M, Toyonaga A, Sasaki E, Tanikawa K. Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A. Gut 36(6), 891-896 (1995).
72. Mueller T, Beutler C, Picó AH et al. Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int. 31(10), 1574-1588 (2011).
73. Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 13(4), 766-772 (1991).
74. Yamada S, Ishii M, Kisara N, Nagatomi R, Toyota T. Macrophages are essential for lymphocyte infiltration in formylpeptide-induced cholangitis in rat liver. Liver 19(3), 253-258 (1999). (Pubitemid 29261593)
75. Pollheimer MJ, Trauner M, Fickert P. Will we ever model PSC? - "it's hard to be a PSC model!". Clin. Res. Hepatol. Gastroenterol. 35(12), 792-804 (2011).
76. Eksteen B, Mora JR, Haughton EL et al. Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology 137(1), 320-329 (2009).
77. Eksteen B, Grant AJ, Miles A et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J. Exp. Med. 200(11), 1511-1517 (2004). (Pubitemid 39657298)
78. Ponsioen CY, Kuiper H, Ten Kate FJ, van Milligen de Wit M, van Deventer SJ, Tytgat GN. Immunohistochemical analysis of inflammation in primary sclerosing cholangitis. Eur. J. Gastroenterol. Hepatol. 11(7), 769-774 (1999). (Pubitemid 29349022)
79. Eksteen B, Miles AE, Grant AJ, Adams DH. Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease. Clin. Med. 4(2), 173-180 (2004). (Pubitemid 39060816)
80. Grant AJ, Lalor PF, Hübscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 33(5), 1065-1072 (2001). (Pubitemid 32378204)
81. Joplin R, Kachilele S. Human intrahepatic biliary epithelial cell lineages: studies in vitro. Methods Mol. Biol. 481, 193-206 (2009).
82. Young VB, Kahn SA, Schmidt TM, Chang EB. Studying the enteric microbiome in inflammatory bowel diseases: getting through the growing pains and moving forward. Front. Microbiol. 2, 144 (2011).
83. Baker DJ, Wijshake T, Tchkonia T et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479(7372), 232-236 (2011).
84. Fickert P, Zollner G, Fuchsbichler A et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123(4), 1238-1251 (2002).
85. Jacquemin E, De Vree JM, Cresteil D et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 120(6), 1448-1458 (2001). (Pubitemid 32322319)
86. Poupon R, Arrive L, Rosmorduc O. The cholangiographic features of severe forms of ABCB4/MDR3 deficiency-associated cholangiopathy in adults. Gastroenterol. Clin. Biol. 34(6-7), 380-387 (2010).
87. van Nieuwerk CM, Groen AK, Ottenhoff R et al. The role of bile salt composition in liver pathology of mdr2 (/) mice: differences between males and females. J. Hepatol. 26(1), 138-145 (1997). (Pubitemid 27072615)
88. Halilbasic E, Fiorotto R, Fickert P et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2/ mice. Hepatology 49(6), 1972-1981 (2009).
89. Tabibian JH, Masyuk AI, Masyuk TV, O'Hara SP, LaRusso NF. Cholangiocyte physiology. Comp. Physiol. 3, 541-565 (2013).
90. Maillette de Buy Wenniger LJ, Oude Elferink RP, Beuers U. Molecular targets for the treatment of fibrosing cholangiopathies. Clin. Pharmacol. Ther. 92(3), 381-387 (2012).
91. Eksteen B, Theron B, Rowe IA, Gunson B. Rapamycin as a novel treatment for recurrent primary sclerosing cholangitis in liver allografts. Hepatology 52(S1), Abstract 335 (2010).
92. Kadomatsu M, Nakajima S, Kato H et al. Cordycepin as a sensitizer to tumour necrosis factor (TNF)-α-induced apoptosis through eukaryotic translation initiation factor 2a (eIF2a)- and mammalian target of rapamycin complex 1 (mTORC1)-mediated inhibition of nuclear factor (NF)-κB. Clin. Exp. Immunol. 168(3), 325-332 (2012).
93. Zheng J, Hudder A, Zukowski K, Novak RF. Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer Lett. 296(1), 74-87 (2010).
94. Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW, Poon RT. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett. 273(2), 201-209 (2009).
95. Gu L, Zhou C, Liu H et al. Rapamycin sensitizes T-ALL cells to dexamethasoneinduced apoptosis. J. Exp. Clin. Cancer Res. 29, 150 (2010).
96. Melum E, Franke A, Schramm C et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat. Genet. 43(1), 17-19 (2011).
97. Tabibian JH, Yeh HC, Singh VK, Cengiz-Seval G, Cameron AM, Gurakar A. Sirolimus may be associated with early recurrence of biliary obstruction in liver transplant patients undergoing endoscopic stenting of biliary strictures. Ann. Hepatol. 10(3), 270-276 (2011).
98. Munshi MK, Uddin MN, Glaser SS. The role of the renin-angiotensin system in liver fibrosis. Exp. Biol. Med. (Maywood) 236(5), 557-566 (2011).
99. Bataller R, Sancho-Bru P, Ginès P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid. Redox Signal. 7(9-10), 1346-1355 (2005). (Pubitemid 41232532)
100. Jonsson JR, Clouston AD, Ando Y et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121(1), 148-155 (2001). (Pubitemid 32591525)
101. Ueki M, Koda M, Yamamoto S, Matsunaga Y, Murawaki Y. Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J. Gastroenterol. 41(10), 996-1004 (2006). (Pubitemid 44741413)
102. Alvaro D, Mancino MG, Glaser S et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 132(1), 415-431 (2007). (Pubitemid 46108729)
103. Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br. J. Pharmacol. 156(1), 7-27 (2009).
104. Kakizaki S, Takizawa D, Tojima H, Horiguchi N, Yamazaki Y, Mori M. Nuclear receptors CAR and PXR; therapeutic targets for cholestatic liver disease. Front. Biosci. 16, 2988-3005 (2011).
105. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 140(6), 1817-1826.e2 (2011).
106. Helmke SM, Wallack A, Herman A, Isberg H, Lauriski S, Everson T. Slow, moderate, and rapid progressors: three distinct categories of patients with primary sclerosing cholangitis detected by functional assessment using cholate testing. Hepatology 56(Suppl. 4), Abstract 2027 (2012).
107. Lankisch TO, Metzger J, Negm AA et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 53(3), 875-884 (2011).
108. Dave M, Elmunzer BJ, Dwamena BA, Higgins PD. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 256(2), 387-396 (2010).
109. Corpechot C, El Naggar A, Poujol-Robert A et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 43(5), 1118-1124 (2006). (Pubitemid 43724636)
110. Talwalkar JA. Elastography for detecting hepatic fibrosis: options and considerations. Gastroenterology 135(1), 299-302 (2008). (Pubitemid 351899031)
111. Isayama H. Current topics in pancreatobiliary endotherapy: what can we do? J. Hepatobiliary Pancreat. Surg. 16(5), 589-591 (2009).
112. Tabibian JH, Streiff MB. Inflammatory bowel disease-associated thromboembolism: a systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis. Inflamm. Bowel Dis. 18(1), 161-171 (2012).
113. Chung MJ, Kim H, Kim KS, Park S, Chung JB, Park SW. Safety evaluation of self-expanding metallic biliary stents eluting gemcitabine in a porcine model. J. Gastroenterol. Hepatol. 27(2), 261-267 (2012).
114. Suk KT, Kim JW, Kim HS et al. Human application of a metallic stent covered with a paclitaxel-incorporated membrane for malignant biliary obstruction: multicenter pilot study. Gastrointest. Endosc. 66(4), 798-803 (2007). (Pubitemid 47495917)
115. Wassef W, Syed I. Designer stents: are we there yet? Gastrointest. Endosc. 66(4), 804-808 (2007). (Pubitemid 47464273)
116. Tabibian JH, Asham EH, Goldstein L et al. Endoscopic treatment with multiple stents for post-liver-transplantation nonanastomotic biliary strictures. Gastrointest. Endosc. 69(7), 1236-1243 (2009).
117. Tabibian JH, Asham EH, Han S et al. Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video). Gastrointest. Endosc. 71(3), 505-512 (2010).
118. Björnsson E, Lindqvist-Ottosson J, Asztely M, Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 99(3), 502-508 (2004). (Pubitemid 38524130)
119. Ponsioen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN. Four years experience with short term stenting in primary sclerosing cholangitis. Am. J. Gastroenterol. 94(9), 2403-2407 (1999). (Pubitemid 29420664)